Individuals with Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) experience neuropsychiatric symptoms following an infection or other trigger. Although PANS is typically described as relapsing-remitting, a large community-based 2017 study revealed a range of courses. The present study examined clinical predictors of symptom persistence, measured as % days symptom-free, in this same sample.
Methods:
A 146-question online survey gathered histories (infections and other triggers, medical and developmental comorbidities), symptomatology, interventions, and outcomes (including school functioning) of PANS patients. Multivariate analyses were applied to examine associations between these variables and % days symptom-free across the disease course.
Results:
Among the 646 subjects included, significant relationships were found between greater symptom persistence and higher rates of medical comorbidities (especially rashes, headaches, chronic sinusitis, frequent diarrhea, and immune deficiencies), developmental diagnoses, and respondent-perceived developmental lags. Subjects with greater symptom persistence were significantly more likely to report PANS exacerbations associated with infections in close contacts, vaccinations, environmental triggers, and exacerbations of comorbidities and were more likely to report PANS recurrences triggered by Epstein Barr Virus, mycoplasma, and sinus infections. More persistent PANS was also associated with significantly higher frequencies of certain symptoms (sleep disturbance, urinary incontinence, muscle pain, brain fog, sensory defensiveness, irritability, and aggression-related symptoms), less effectiveness of intravenous immunoglobulin in combating symptoms, and more difficulty attending school.
Conclusions:
Our results suggest high symptom persistence in PANS to be associated with more pervasive medical and neuropsychiatric symptoms. Differences in symptom persistence are associated with both intrinsic (e.g., immune competence) and extrinsic (e.g., infections, treatment) factors. Because extrinsic factors are potentially modifiable, it is critical that providers be aware of current guidelines on PANS evaluation and treatment.
Get full access to this article
View all access options for this article.
References
1.
AnanthakrishnanAN, KhaliliH, PanA, et al.Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: Results from the Nurses' Health Study. Clin Gastroenterol Hepatol, 2013; 11:57–62.
2.
BatesD.Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology, 2011; 76(1 Suppl 1):S14–S25; doi: 10.1212/WNL.0b013e3182050388
3.
BauerME, TeixeiraAL. Inflammation in psychiatric disorders: What comes first?. Ann NY Acad Sci, 2019; 1437:57–67; doi: 10.1111/nyas.13712
4.
BollenJ, TrickL, et al.The effects of acute inflammation on cognitive functioning and emotional processing in humans: A systematic review of experimental studies. J Psychosom Res, 2017; 94:47–55; doi: 10.1016/j.jpsychores.2017.01.002
5.
Calaprice-WhittyD, TangA, TonaJ. Factors associated with symptom persistence in PANS: Part I—access to care. J Child Adolesc Psychopharmacol, 2023; 33(9):356–364; doi: 10.1089/cap.2023.0022
6.
CalapriceD, TonaJ, Parker-AthillC, et al.A survey of PANS characteristics and course. J Child Adolesc Psychopharmacol, 2017; 27(7):607–618; doi: 10.1089/cap.2016.0105
7.
CalapriceD, TonaJ, MurphyT.Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. J Child Adolesc Psychopharmacol, 2018, 28(2):92–103; doi: 10.1089/cap.2017.0101
8.
ChanA, PhuT, FarhadianB, et al.Familial clustering of immune-mediated diseases in children with abrupt-onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol, 2020; 30(5):345–346; doi: 10.1089/cap.2019.0167
9.
ChangK, FrankovichJ, CooperstockM, et al.PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol, 2015; 25(1):3–13; doi: 10.1089/cap.2014.0084
10.
ChangYJ, TsengJC, LeongPY, et al.Increased risk of Sjögren's syndrome in patients with obsessive-compulsive disorder: A nationwide population-based Cohort Study. Int J Environ Res Public Health, 2021; 18(11):5936; doi: 10.3390/ijerph18115936
11.
CooperstockMS, SwedoSE, PasternackMS, et al.Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III-Treatment and Prevention of Infections. J Child Adolesc Psychopharmacol, 2017; 27(7):594–606; doi: 10.1089/cap.2016.0151
DickersonF, StallingsC, et al.C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res, 2007; 93(1–3):261–265; doi: 10.1016/j.schres.2007.03.022
14.
FernellE, SundinM, FasthA, et al.Paediatric Acute onset Neuropsychiatric Syndrome: Exploratory study finds no evidence of HLA class II association but high rate of autoimmunity in first-degree relatives. Acta Paediatr, 2021; 111:820–824; doi: 10.1111/apa.15805
15.
FrankovichJ, ThienemannM, PearlsteinJ, et al.Multidisciplinary clinic dedicated to treating youth with pediatric acute-onset neuropsychiatric syndrome: Presenting characteristics of the first 47 consecutive patients. J Child Adolesc Psychopharmacol, 2015; 25(1):38–47; doi: 10.1089/cap.2014.0081
16.
FrankovichJ, SwedoS, MurphyT, et al.Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part II-Use of immunomodulatory therapies. J Child Adolesc Psychopharmacol, 2017; 27(7):574–593; doi: 10.1089/cap.2016.0148
17.
GromarkC, HesselmarkE, DjupedalIG, et al.A two-to-five year follow-up of a pediatric acute-onset neuropsychiatric syndrome cohort. Child Psychiatry Hum Dev, 2022; 53:354–364; doi.org/10.1007/s10578-021-01135-4
18.
GrovenN, ForsE, IversenVC, et al.Association between cytokines and psychiatric symptoms in chronic fatigue syndrome and healthy controls. Nordic J Psychiatry, 2018; 72(8):556–560; doi: 10.1080/08039488.2018.1493747
19.
HansenN, LippM, VogelgsangJ, et al.Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. Brain Behav Immunity Health, 2020; 9:100–154; doi: 10.1016/j.bbih.2020.100154
20.
HoffmanJ, EnkA. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol, 2019; 10:1090; doi: 10.3389/fimmu.2019.01090
21.
HuangX, HussainB, ChangJ. Peripheral inflammation and blood–brain barrier disruption: Effects and mechanisms. CNS Neurosci Ther, 2021; 27:36–47; doi: 10.1111/cns.13569
JohnsonM, FernellE, PredaI, et al.Paediatric acute-onset neuropsychiatric syndrome in children and adolescents: An observational cohort study. Lancet Child Adolesc Health, 2019; 3(3):175–180; doi: 10.1016/s2352-4642(18)30404-8
24.
The Joint Commission, Diagnostic overshadowing among groups experiencing health disparities. Sentinal Event Alert: A complimentary publication of The Joint commission. 2022; 65. Available from: https://www.jointcommission.org/-/media/tjc/documents/resources/patient-safety-topics/sentinel-event/sea-65-diagnostic-overshadowing-6-16-22-final.pdf [Last accessed: September26, 2023].
25.
Katz-AgranovN, KhattriS, Zandman-GoddardG. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev, 2015; 14(8):651–658; doi: 10.1016/j.autrev.2015.04.003
26.
KoganS, OspinaLH, MittalVA, et al.The impact of inflammation on neurocognition and risk for psychosis: A critical review. Eur Arch Psychiatry Clin Neurosci, 2020; 270(7):793–802; doi: 10.1007/s00406-019-01073-2
27.
LepriG, RiganteD, BellandoRS, et al.Clinical-serological characterization and treatment outcome of a large cohort of italian children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection and pediatric acute neuropsychiatric syndrome. J Child Adolesc Psychopharmacol, 2019; 29(8):608–614; doi: 10.1089/cap.2018.0151
28.
MaM, SandbergJ, FarhadianB, et al.Arthritis in children with psychiatric deteriorations: A case series. Dev Neurosci, 2023; 12:1; doi: 10.1159/000530854
29.
MillerAH.Beyond depression: The expanding role of inflammation in psychiatric disorders. World Psychiatry, 2020; 19(1):108–109; doi: 10.1002/wps.20723
30.
MorellA.Clinical relevance of IgG subclass deficiencies. Ann Biol Clin (Paris), 1994; 52(1):49–52.
31.
MulhearnB, BruceI. Indications for IVIG in rheumatic diseases. Rheumatology, 2015; 54(3):383–391; doi: 10.1093/rheumatology/keu429
32.
MurphyTK, PatelPD, McGuireJF, et al.Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype. J Child Adolesc Psychopharmacol, 2015; 25(1):14–25.
33.
MurphyTK, StorchEA, TurnerJM, et al.Maternal history of autoimmune disease in children presenting with Tics and/or obsessive-compulsive disorder. J Neuroimmunol, 2010; 229(1–2):243–247; doi: 10.1016/j.jneuroim.2010.08.017
34.
PeduzziP, ConcatoJ, KemperE, et al.A simulation study of the number of events per variable in logistic regression analysis, J Clin Epidemiol, 1996; 49(12):1373–1379; doi: 10.1016/S0895-4356(96)00236-3
35.
PlattMP, AgalliuD, CutforthT. Hello from the other side: How autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol, 2017; 21(8):442; doi: 10.3389/fimmu.2017.00442
36.
SchwartzN, StockAD, PuttermanC. Neuropsychiatric lupus: New mechanistic insights and future treatment directions. Nat Rev Rheumatol, 2019; 15(3):137–152; doi: 10.1038/s41584-018-0156-8
37.
ShoenfeldY, KatzU. IVIg therapy in autoimmunity and related disorders: Our experience with a large cohort of patients. Autoimmunity, 2005; 38(2):123–137; doi: 10.1080/08916930500059633
38.
SorensenPS.The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci, 2003; 206(2):123–130; doi: 10.1016/s0022-510x(02)00343-x
39.
SwedoSE, FrankovichJ, MurphyTK. Overview of treatment of pediatric acute-onset neuropsychiatric syndrome. J Child Adolesc Psychopharmacol, 2017; 27(7):562–565; doi: 10.1089/cap.2017.0042
40.
SwedoS, LeckmanJ, RoseN. From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Pediatr Ther, 2012; 2(2):161–0665.10001; doi: 10.4172/2161-0665.1000113
41.
ThienemannM, MurphyT, LeckmanJ, et al.Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part I-psychiatric and behavioral interventions. J Child Adolesc Psychopharmacol, 2017; 27(7):566–573; doi: 10.1089/cap.2016.0145
42.
TonaJ, BhattacharjyaS, CalapriceD. Impact of PANS and PANDAS exacerbations on occupational performance: A Mixed-Methods Study. Am J Occup Ther, 2017; 71(3):7103220020P1-7103220020P9; doi: 10.5014/ajot.2017.022285
43.
TonaJ, PosnerT. Pediatric autoimmune neuropsychiatric disorders: A new frontier for occupational therapy intervention. OT Practice, 2011; 14–19.
44.
Van ErpIAM, MichailidouI, van EssenTA, et al.Tackling neuroinflammation after traumatic brain injury: Complement inhibition as a therapy for secondary injury. Neurotherapeutics, 2022:19(6):284–303; doi: 10.1007/s13311-022-01306-8
45.
WalkerJR, EdigerJP, GraffLA, et al.The Manitoba IBD Cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol, 2008; 103:1989–1997; doi: 10.1111/j.1572-0241.2008.01980.x
46.
YarlagaddaA, AlfsonE, ClaytonA. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgemont), 2009; 6(11):18–22.
